Current clinical data indicate that the MEK inhibitor trametinib extends progression-free survival of patients with BRAF mutant melanomas by 3.3 months beyond that observed with dacarbazine (1.5 months)6 but not of patients with BRAF wild-type melanomas, irrespective of NRAS mutation status58. The gene discussed is NRAS; the disease is melanoma.